A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

This study is testing an experimental cancer vaccine called mRNA-4157 to see if it can help the body’s own immune system better identify and fight solid tumor cancers. By combining this vaccine with existing immunotherapy, researchers hope to find new, more effective ways to treat various types of cancer.

This trial is designed for people with specific types of solid tumors, such as certain lung or pancreatic cancers. Eligibility depends on your cancer's stage, previous treatments, and your overall health, so you would need to discuss your medical history with the study team.

Participants will receive the experimental vaccine, either alone or alongside standard immunotherapy drugs. Throughout the process, the medical team will monitor you closely to check for side effects and to see how your body responds to the treatment.

The study is currently active but is no longer accepting new patients. It is being conducted at medical centers in Los Angeles, Washington D.C., and Orlando.